
<!DOCTYPE html>
<html>
<head>
    <meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0">
    <title>GI Intelligence Terminal</title><script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <style>
        :root { --primary: #3498db; --success: #2ecc71; --warning: #ffb300; --bg: #f5f7fa; --text: #2c3e50; }
        body { font-family: -apple-system, sans-serif; background: var(--bg); color: var(--text); margin: 0; padding: 8px; }
        .card { background: #fff; border-radius: 12px; padding: 12px; box-shadow: 0 2px 8px rgba(0,0,0,0.05); margin-bottom: 12px; border: 1px solid #e0e0e0; }
        
        /* ğŸ© ë„í‘œ ì¤‘ì•™ ë°°ì¹˜ ìŠ¤íƒ€ì¼ */
        .chart-container { background: #fff; border-radius: 12px; padding: 12px; border: 1px solid #e0e0e0; height: 160px; display: flex; justify-content: center; margin-bottom: 12px; }
        
        .paper-item { margin-bottom: 8px; border-radius: 10px; overflow: hidden; list-style: none; border: 1px solid #eee; }
        summary { padding: 12px; cursor: pointer; outline: none; list-style: none; }
        summary::-webkit-details-marker { display: none; }
        .meta { font-size: 0.7rem; color: #7f8c8d; margin-bottom: 4px; display: flex; align-items: center; gap: 4px; flex-wrap: wrap; }
        .title-row { font-weight: bold; font-size: 0.9rem; line-height: 1.4; display: flex; align-items: flex-start; }
        .arrow-icon { display: inline-block; transition: transform 0.2s; color: var(--primary); margin-right: 6px; flex-shrink: 0; }
        details[open] .arrow-icon { transform: rotate(90deg); }
        .badge { padding: 1px 4px; border-radius: 3px; font-size: 0.6rem; font-weight: bold; color: #fff; }
        .rct { background: #e74c3c; } .gl { background: var(--success); } .if { background: #8e44ad; }
        .content { padding: 12px; background: #f9f9f9; border-top: 1px solid #eee; font-size: 0.85rem; }
        .clinical-note { background: #fff8e1; border-left: 3px solid var(--warning); padding: 10px; border-radius: 6px; margin-bottom: 10px; font-size: 0.8rem; color: #5d4037; }
        .btm-box { background: #ebf5ff; padding: 10px; border-radius: 6px; margin-bottom: 10px; border-left: 3px solid var(--primary); font-weight: bold; }
        .btn { flex: 1; padding: 8px; border-radius: 6px; text-align: center; text-decoration: none; font-weight: bold; cursor: pointer; font-size: 0.8rem; border: none; color: #fff; }
        .pub { background: var(--primary); } .shr { background: var(--success); }
        h3 { font-size: 1.1rem; margin: 15px 0 10px 0; border-bottom: 2px solid #eee; padding-bottom: 5px; }
    </style>
</head>
<body>
    <div class="card" style="text-align:center;">
        <h1 style="margin:0; font-size:1.4rem;">ğŸ¥ GI Intel Terminal</h1>
        <small style="font-size:0.75rem;">Updated: 2026-02-27 17:00 KST</small>
    </div>
    
    <div class="card" style="border-top: 5px solid #e74c3c;">
        <h2 style="margin-top:0; font-size:1rem; color:#e74c3c;">ğŸ”¥ Weekly Top 3 (Practice-Changing)</h2>
        
    <details class="paper-item" style="border-left:5px solid #e74c3c;background:#fffafa;">
        <summary>
            <div class="meta"> <b>Giornale italiano di cardiologia (2006)</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>[Non-dilated left ventricular cardiomyopathy: beyond morphology, towards diagnostic precision].</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The introduction of non-dilated left ventricular cardiomyopathy (NDLVC) represents one of the key highlights of the 2023 European Society of Cardiology guidelines on cardiomyopathies. NDLVC is defined by the presence of left ventricular systolic dysfunction in the absence of ventricular dilation and/or non-ischemic myocardial fibrosis detectable by cardiac magnetic resonance. The clinical manifestation may be arrhythmogenic, with a risk of life-threatening ventricular arrhythmias even in patients with preserved ejection fraction. The phenotypic heterogeneity and variability in clinical expression reflect the complex interplay between genetic predisposition (involving variants in genes such as FLNC, DSP, and LMNA) and environmental, epigenetic, or inflammatory factors. A synergistic approach combining comprehensive clinical and family assessment, electrocardiographic and echocardiographic findings, advanced imaging, and genetic testing enables more accurate phenotypic characterization, definitive diagnosis, and consequently, tailored therapeutic strategies.</div>
            <div class="abs">The introduction of non-dilated left ventricular cardiomyopathy (NDLVC) represents one of the key highlights of the 2023 European Society of Cardiology guidelines on cardiomyopathies. NDLVC is defined by the presence of left ventricular systolic dysfunction in the absence of ventricular dilation and/or non-ischemic myocardial fibrosis detectable by cardiac magnetic resonance. The clinical manifestation may be arrhythmogenic, with a risk of life-threatening ventricular arrhythmias even in patients with preserved ejection fraction. The phenotypic heterogeneity and variability in clinical expression reflect the complex interplay between genetic predisposition (involving variants in genes such as FLNC, DSP, and LMNA) and environmental, epigenetic, or inflammatory factors. A synergistic approach combining comprehensive clinical and family assessment, electrocardiographic and echocardiographic findings, advanced imaging, and genetic testing enables more accurate phenotypic characterization, definitive diagnosis, and consequently, tailored therapeutic strategies.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41738421/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41738421')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41738421" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ [Non-dilated left ventricular cardiomyopathy: beyond morphology, towards diagnostic precision].\nğŸ¥ Giornale italiano di cardiologia (2006)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41738421/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:5px solid #e74c3c;background:#fffafa;">
        <summary>
            <div class="meta"> <b>Journal of personalized medicine</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ IL-12/23 ë°˜ì‘ í‰ê°€</div>
        <div><b>âš¡ Action:</b> âœ… ìš°ì„  ì ìš© ê³ ë ¤</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Interleukin-23 (IL-23) is a pivotal cytokine driving intestinal inflammation in inflammatory bowel disease (IBD). The development of monoclonal antibodies selectively targeting the p19 subunit of IL-23, including risankizumab, mirikizumab and guselkumab, has significantly expanded the therapeutic landscape of IBD. Landmark phase 3 trials in Crohn's disease (CD) and ulcerative colitis (UC) have demonstrated high efficacy and durable responses, followed by recent regulatory approvals across both indications. Notably, the SEQUENCE trial established the superiority of risankizumab over ustekinumab in achieving endoscopic and clinical endpoints in CD, underscoring the therapeutic value of IL-23p19 blockade and its differentiation from prior p40 inhibition. With additional agents in advanced development, IL-23p19 inhibitors are now emerging as a bona fide treatment class in IBD. Furthermore, IL-23p19 inhibitors display favorable safety profiles and convenient subcutaneous administration regimens, which broaden their applicability across diverse patient populations. However, key knowledge gaps remain regarding optimal treatment positioning, comparative effectiveness, and long-term disease outcomes. Precision medicine approaches will be crucial to fully exploit the potential of this drug class. For instance, early biomarkers can help monitor response, while future integration of serological and multi-omics biomarkers may enable the prediction of treatment success and guide personalized selection. This review summarizes the current knowledge base regarding IL-23p19 inhibitors in IBD, highlights their class effects and unique clinical value, and outlines a research agenda towards biomarker-driven and precision-guided use. Ultimately, IL-23p19-inhibition exemplifies how targeted immunotherapy and precision medicine can converge in order to reshape IBD management.</div>
            <div class="abs">Interleukin-23 (IL-23) is a pivotal cytokine driving intestinal inflammation in inflammatory bowel disease (IBD). The development of monoclonal antibodies selectively targeting the p19 subunit of IL-23, including risankizumab, mirikizumab and guselkumab, has significantly expanded the therapeutic landscape of IBD. Landmark phase 3 trials in Crohn's disease (CD) and ulcerative colitis (UC) have demonstrated high efficacy and durable responses, followed by recent regulatory approvals across both indications. Notably, the SEQUENCE trial established the superiority of risankizumab over ustekinumab in achieving endoscopic and clinical endpoints in CD, underscoring the therapeutic value of IL-23p19 blockade and its differentiation from prior p40 inhibition. With additional agents in advanced development, IL-23p19 inhibitors are now emerging as a bona fide treatment class in IBD. Furthermore, IL-23p19 inhibitors display favorable safety profiles and convenient subcutaneous administration regimens, which broaden their applicability across diverse patient populations. However, key knowledge gaps remain regarding optimal treatment positioning, comparative effectiveness, and long-term disease outcomes. Precision medicine approaches will be crucial to fully exploit the potential of this drug class. For instance, early biomarkers can help monitor response, while future integration of serological and multi-omics biomarkers may enable the prediction of treatment success and guide personalized selection. This review summarizes the current knowledge base regarding IL-23p19 inhibitors in IBD, highlights their class effects and unique clinical value, and outlines a research agenda towards biomarker-driven and precision-guided use. Ultimately, IL-23p19-inhibition exemplifies how targeted immunotherapy and precision medicine can converge in order to reshape IBD management.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41745409/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41745409')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41745409" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.\nğŸ¥ Journal of personalized medicine\nâš¡ âœ… ìš°ì„  ì ìš© ê³ ë ¤\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41745409/</textarea>
        </div>
    </details>
    </div>

    <div class="chart-container">
        <canvas id="c2"></canvas>
    </div>

    <div class="card">
        <button id="fBtn" onclick="toggleF()" style="width:100%; padding:10px; border-radius:20px; border:1px solid var(--success); background:#fff; color:var(--success); font-weight:bold; cursor:pointer; font-size: 0.85rem;">ğŸ“‹ ê°€ì´ë“œë¼ì¸ë§Œ ë³´ê¸°</button>
        <div class='sec-group'><h3>ğŸ GI Track</h3>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"><span class='badge if'>IF 29.4</span> <b>Gastroenterology</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>The effect of dose-intensification after secondary loss of response to ustekinumab in Crohn's disease: Results of the REScUE study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ IL-12/23 ë°˜ì‘ í‰ê°€</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>In patients with CD and secondary loss of response to ustekinumab, dose-intensification with a single intravenous administration and followed by 4 weekly subcutaneous dosing of ustekinumab was not more effective than one intravenous administration followed by 8 weekly SC dosing of ustekinumab.</div>
            <div class="abs">Secondary loss of response to ustekinumab is observed in patients with Crohn's disease (CD). Multiple dose-intensification regimens have been proposed. We aimed to test prospectively two different dose-intensification regimens with ustekinumab in patients with CD experiencing secondary loss of response.<br><br>This was an investigator-initiated, multicenter, randomized, placebo-controlled trial conducted at 15 hospitals in Belgium. Eligible patients were adults with CD treated with ustekinumab on maintenance dosing of 90 mg subcutaneous q8 weeks and experiencing a secondary loss of response (PRO-2: abdominal pain (AP) score >1 and liquid or very soft stool frequency (SF) >3 and an objective documentation of disease). Patients were randomized 1:1 to receiving a single intravenous re-induction with ustekinumab â‰ˆ 6mg/kg followed by either subcutaneous ustekinumab 90 mg q4 weeks or q8 weeks till week 48. The primary endpoint was the proportion of patients with steroid-free clinical remission at week 48, defined as PRO-2 remission: (AP â‰¤ 1 AND SF â‰¤3) and fecal calprotectin <250Î¼g/g and no steroids in the 90 days prior to week 48.<br><br>Between March 2020 and October 2023, 108 patients were randomized. Steroid free clinical remission at week 48 was reached in 15% versus 19% of patients in the Q4W versus the Q8W group (difference 4%; p=0.5). Serious adverse events occurred in 17% vs 13% of patients.<br><br>In patients with CD and secondary loss of response to ustekinumab, dose-intensification with a single intravenous administration and followed by 4 weekly subcutaneous dosing of ustekinumab was not more effective than one intravenous administration followed by 8 weekly SC dosing of ustekinumab.<br><br>gov number: NCT04245215.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41747777/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41747777')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41747777" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ The effect of dose-intensification after secondary loss of response to ustekinumab in Crohn's disease: Results of the REScUE study.\nğŸ¥ Gastroenterology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41747777/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Frontiers in pharmacology</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously. These results support the continued safe use of GLP-1 RAs in T2DM and obesity, although longer trials with cancer-specific endpoints are warranted. This review was registered in Open Science Framework https://osf.io/3rv6d/overview.</div>
            <div class="abs">Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for type 2 diabetes mellitus (T2DM) and obesity. While their metabolic benefits are established, concerns persist about a possible link with gastrointestinal (GI) cancers. This study aimed to clarify the association between GLP-1 RA use and GI cancer risk.<br><br>A systematic search of PubMed, Embase, and Scopus till August 2024 identified randomized controlled trials (RCTs) reporting GI cancer outcomes. Ninety-three RCTs with 1.85 million participants were included. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random-effects model, with subgroup analyses by cancer type and exposure duration.<br><br>GLP-1 RA use was not associated with an increased overall risk of GI cancers (HR 0.81: 95% CI: 0.68-0.96). Subgroup analyses indicated reduced risks of colorectal cancer (HR 0.81: 95% CI: 0.68-0.96) and liver cancer (HR: 0.74; 95% CI: 0.62-0.88). Pancreatic cancer risk was not significantly elevated (HR: 0.78; 95% CI: 0.61-0.95). Findings were consistent across sensitivity analyses.<br><br>This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously. These results support the continued safe use of GLP-1 RAs in T2DM and obesity, although longer trials with cancer-specific endpoints are warranted. This review was registered in Open Science Framework https://osf.io/3rv6d/overview.<br><br>https://osf.io/3rv6d/overview.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41743116/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41743116')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41743116" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.\nğŸ¥ Frontiers in pharmacology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41743116/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>BMC medicine</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Minimum 18-week chemotherapy improves survival in locally advanced rectal cancer after neoadjuvant radiotherapy: a post hoc analysis of the STELLAR trial.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The STELLAR trial was registered at ClinicalTrials.gov (identifier: NCT02533271); however, this post hoc analysis was retrospectively conducted.</div>
            <div class="abs">The survival benefit of adjuvant chemotherapy after chemoradiotherapy in locally advanced rectal cancer (LARC) remains unproven, whereas total neoadjuvant therapy (TNT) incorporating preoperative chemotherapy has demonstrated improved outcomes. However, the total chemotherapy duration delivered across neoadjuvant and adjuvant phases varies substantially in clinical practice. We investigated the impact of total chemotherapy duration in the STELLAR trial.<br><br>This post hoc analysis was based on the phase III randomized trial, comparing short-course radiotherapy followed by four cycles of chemotherapy (TNT) with long-course chemoradiotherapy (CRT) in LARC patients. Five hundred thirty-nine patients with available chemotherapy duration data were included, with a median follow-up of 68.1 months. Patients were categorized: group 1 (no chemotherapy, nâ€‰=â€‰121), group 2 (3 to 12 weeks, nâ€‰=â€‰113), group 3 (15 weeks, nâ€‰=â€‰30), and group 4 (â‰¥â€‰18 weeks, nâ€‰=â€‰275). Disease-free survival (DFS), overall survival (OS), distant metastasis (DM), and locoregional recurrence (LRR) were assessed using time-dependent Cox regression.<br><br>Group 4 achieved the highest 5-year OS (82.1%) and DFS (66.0%) rates. Compared with groups 1 and 2, group 4 demonstrated significantly improved OS (adj. Pâ€‰â‰¤â€‰0.001) and improved DFS versus group 1 (HR 0.621, 95% CI 0.443-0.870, adj. Pâ€‰=â€‰0.017). In the TNT cohort, group 4 was associated with significantly improved OS and DFS compared with group 2 (adj. Pâ€‰<â€‰0.01), but not with group 3. Additionally, group 4 showed a significantly lower risk of LRR than group 3. In the CRT cohort, group 4 was associated with improved OS compared with group 1 (adj. Pâ€‰=â€‰0.005); however, this association was not retained in surgical patients. No significant differences in DFS, DM, or LRR were observed across groups in the CRT cohort.<br><br>In TNT cohort, minimum 18 weeks of chemotherapy was associated with improved OS and DFS compared to 3 to 12 weeks. The observed OS benefit of minimum 18 weeks versus no chemotherapy in the CRT cohort was not retained among surgical patients. These findings suggest caution in shortening chemotherapy duration, particularly in high-risk patients treated with TNT, and warrant confirmation in prospective TNT-specific trials.<br><br>The STELLAR trial was registered at ClinicalTrials.gov (identifier: NCT02533271); however, this post hoc analysis was retrospectively conducted.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41742206/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41742206')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41742206" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Minimum 18-week chemotherapy improves survival in locally advanced rectal cancer after neoadjuvant radiotherapy: a post hoc analysis of the STELLAR trial.\nğŸ¥ BMC medicine\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41742206/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Diseases (Basel, Switzerland)</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn's Disease.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ Anti-TNF ìœ ì§€/TDM ê³ ë ¤</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ Dose escalation ê³ ë ¤</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Upadacitinib demonstrates significant clinical and endoscopic efficacy in biologic-experienced, anti-TNF-pretreated patients with CD, achieving remission rates comparable to or exceeding those of the pivotal trials despite a highly refractory population (75% with â‰¥3 prior biologic failures). The favorable safety profile supports upadacitinib as an important therapeutic option in sequential treatment of refractory CD.</div>
            <div class="abs">The efficacy of upadacitinib in patients with Crohn's disease (CD) has been shown in pivotal randomized controlled trials. However, real-world data is needed to assess its effectiveness and safety in routine clinical care with biologic-experienced patients. This study aimed to evaluate the clinical and endoscopic efficacy, patient-reported outcomes (PROs), and safety of upadacitinib in biologic-experienced patients with CD in a real-world setting.<br><br>This prospective bi-centric real-world study enrolled 28 anti-TNF-experienced patients with CD receiving upadacitinib 45 mg daily for 12 weeks (induction), followed by 30 mg daily maintenance through week 52. Primary endpoints included endoscopic response (â‰¥50% SES-CD reduction or â‰¥2-point decrease from baseline for baseline SES-CD â‰¤ 4) and clinical remission (Harvey-Bradshaw Index [HBI] â‰¤ 4). Secondary endpoints included endoscopic remission, clinical response (HBI decrease â‰¥ 3 points), and quality of life (IBD-Disk). Statistical analysis used the Wilcoxon signed-rank test with 95% confidence intervals (CIs).<br><br>Median patient age was 37 years; 75% had â‰¥3 prior biologic failures. Clinical remission rates (HBI) were 59% (95% CI: 41-75%) at week 12, 44% (95% CI: 27-63%) at week 26, and 53% (95% CI: 29-76%) at week 52. Endoscopic response rates were 48% (95% CI: 44-52%) at week 26 and 46% (95% CI: 21-72%) at week 52. Endoscopic remission was achieved in 43% (95% CI: 40-48%) at week 26 and 27% (95% CI: 10-57%) at week 52. Clinical response (HBI) improved progressively from 65% at week 2 to 71% at week 52. Quality of life, as assessed by the IBD-Disk, showed significant improvement: Reduced Disease Burden (defined as a decrease of 70% or a CED-Disk Score of â‰¤15) was observed in 33% of patients at week 12 and 35% at week 52. Median SES-CD decreased from 9 points (IQR: 6-17) at baseline to 5 points (IQR: 1-12, <br><br>Upadacitinib demonstrates significant clinical and endoscopic efficacy in biologic-experienced, anti-TNF-pretreated patients with CD, achieving remission rates comparable to or exceeding those of the pivotal trials despite a highly refractory population (75% with â‰¥3 prior biologic failures). The favorable safety profile supports upadacitinib as an important therapeutic option in sequential treatment of refractory CD.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41745092/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41745092')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41745092" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn's Disease.\nğŸ¥ Diseases (Basel, Switzerland)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41745092/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Blood</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Inflammatory Bowel Disease-induced Inflammation Augments Clonal Hematopoiesis of Indeterminate Potential through Ref-1.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by age-related somatic mutations in hematopoietic stem and progenitor cells (HSC/Ps) and is correlated with an increased risk of myeloid malignancies, elevated inflammatory pathways in circulating myeloid cells, higher all-cause mortality, chronic kidney disease, and cardiovascular disease. The pathophysiology of inflammatory bowel disease (IBD) is intrinsically linked to heightened inflammation. Nevertheless, the presence of CHIP in IBD and its role in the pathophysiology of IBD remains poorly elucidated. In the UK Biobank, CHIP was associated with an increased incidence of IBD. Females with CHIP had a 1.33-fold higher risk, which was further validated in All of Us data base (ÃŸOR = 1.29). For Crohn's disease, DNMT3A mutations conferred a 1.81-fold increased incidence in females compared to non-DNMT3A-carriers, which rose to 2.09 for large clones (variant allele fraction â‰¥10%). In contrast, for ulcerative colitis, TET2 large clones were significantly associated, and only among individuals under 45. These associations were further identified using two-sample Mendelian randomization. In a mouse model of CHIP-IBD, HSC/Ps with Dnmt3a mutation demonstrated significantly worse pathophysiology compared to controls, due in part to heightened expression of Apurinic/apyrimidinic endonuclease 1 (APE1) in the bone marrow and colon. Treatment with the APE1/Ref-1 inhibitor APX3330 ameliorated CHIP-IBD driven by the Dnmt3a mutation.</div>
            <div class="abs">Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by age-related somatic mutations in hematopoietic stem and progenitor cells (HSC/Ps) and is correlated with an increased risk of myeloid malignancies, elevated inflammatory pathways in circulating myeloid cells, higher all-cause mortality, chronic kidney disease, and cardiovascular disease. The pathophysiology of inflammatory bowel disease (IBD) is intrinsically linked to heightened inflammation. Nevertheless, the presence of CHIP in IBD and its role in the pathophysiology of IBD remains poorly elucidated. In the UK Biobank, CHIP was associated with an increased incidence of IBD. Females with CHIP had a 1.33-fold higher risk, which was further validated in All of Us data base (ÃŸOR = 1.29). For Crohn's disease, DNMT3A mutations conferred a 1.81-fold increased incidence in females compared to non-DNMT3A-carriers, which rose to 2.09 for large clones (variant allele fraction â‰¥10%). In contrast, for ulcerative colitis, TET2 large clones were significantly associated, and only among individuals under 45. These associations were further identified using two-sample Mendelian randomization. In a mouse model of CHIP-IBD, HSC/Ps with Dnmt3a mutation demonstrated significantly worse pathophysiology compared to controls, due in part to heightened expression of Apurinic/apyrimidinic endonuclease 1 (APE1) in the bone marrow and colon. Treatment with the APE1/Ref-1 inhibitor APX3330 ameliorated CHIP-IBD driven by the Dnmt3a mutation.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41746260/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41746260')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41746260" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Inflammatory Bowel Disease-induced Inflammation Augments Clonal Hematopoiesis of Indeterminate Potential through Ref-1.\nğŸ¥ Blood\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41746260/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Scientific reports</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Imputation methods for serologic biomarkers in inflammatory bowel disease.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Serologic biomarkers have emerged as a powerful tool for the diagnosis of Inflammatory Bowel Disease (IBD) and the differentiation between subgroups of IBD. However, missingness in serologic data can adversely affect the efficacy of any form of statistical or machine learning analysis, leading to biased predictions. This paper provides a thorough comparison of multiple imputation models that can be used for the imputation of serologic data under different missingness scenarios. All major forms of missingness, including Missing Completely at Random (MCAR), Missing at Random (MAR), and Missing Not at Random (MNAR), were explored in relation to the serologic data. The imputation models used in this study encompass Multiple Imputation (MI) using Chained Equations (MICE), Iterative Imputer (II), and Autoencoders (AE). Across three real IBD cohorts and 2,400 simulated scenarios spanning MCAR/MAR/MNAR and 5-40% missingness, we evaluated imputers on direct accuracy, inferential signal, and predictive utility. No single method is universally optimal: iterative imputers (II-BR/KNN/RF) tend to lead at low-moderate missingness, whereas autoencoder-based (AE/VAE) approaches are more robust as missingness increases; all analyses are performed within-cohort to avoid information leakage.</div>
            <div class="abs">Serologic biomarkers have emerged as a powerful tool for the diagnosis of Inflammatory Bowel Disease (IBD) and the differentiation between subgroups of IBD. However, missingness in serologic data can adversely affect the efficacy of any form of statistical or machine learning analysis, leading to biased predictions. This paper provides a thorough comparison of multiple imputation models that can be used for the imputation of serologic data under different missingness scenarios. All major forms of missingness, including Missing Completely at Random (MCAR), Missing at Random (MAR), and Missing Not at Random (MNAR), were explored in relation to the serologic data. The imputation models used in this study encompass Multiple Imputation (MI) using Chained Equations (MICE), Iterative Imputer (II), and Autoencoders (AE). Across three real IBD cohorts and 2,400 simulated scenarios spanning MCAR/MAR/MNAR and 5-40% missingness, we evaluated imputers on direct accuracy, inferential signal, and predictive utility. No single method is universally optimal: iterative imputers (II-BR/KNN/RF) tend to lead at low-moderate missingness, whereas autoencoder-based (AE/VAE) approaches are more robust as missingness increases; all analyses are performed within-cohort to avoid information leakage.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41748696/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41748696')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41748696" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Imputation methods for serologic biomarkers in inflammatory bowel disease.\nğŸ¥ Scientific reports\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41748696/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Toxins</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Indoxyl Sulfate in the Gut-Kidney Axis: Pathophysiology and Clinical Significance in CKD-Associated Colorectal Cancer.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Chronic Kidney Disease (CKD) and Colorectal Cancer (CRC) share a profound epidemiological link, supported by Mendelian randomization studies suggesting causality. This review articulates a refined Gut-Kidney Axis, focusing on the pathophysiology of indole-derived uremic toxins. CKD-induced dysbiosis drives hepatic synthesis and systemic accumulation of indoxyl sulfate, which is proposed to promote carcinogenesis via Aryl Hydrocarbon Receptor (AhR) and Akt signaling, ultimately upregulating </div>
            <div class="abs">Chronic Kidney Disease (CKD) and Colorectal Cancer (CRC) share a profound epidemiological link, supported by Mendelian randomization studies suggesting causality. This review articulates a refined Gut-Kidney Axis, focusing on the pathophysiology of indole-derived uremic toxins. CKD-induced dysbiosis drives hepatic synthesis and systemic accumulation of indoxyl sulfate, which is proposed to promote carcinogenesis via Aryl Hydrocarbon Receptor (AhR) and Akt signaling, ultimately upregulating </div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41745738/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41745738')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41745738" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Indoxyl Sulfate in the Gut-Kidney Axis: Pathophysiology and Clinical Significance in CKD-Associated Colorectal Cancer.\nğŸ¥ Toxins\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41745738/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Journal of personalized medicine</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ IL-12/23 ë°˜ì‘ í‰ê°€</div>
        <div><b>âš¡ Action:</b> âœ… ìš°ì„  ì ìš© ê³ ë ¤</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Interleukin-23 (IL-23) is a pivotal cytokine driving intestinal inflammation in inflammatory bowel disease (IBD). The development of monoclonal antibodies selectively targeting the p19 subunit of IL-23, including risankizumab, mirikizumab and guselkumab, has significantly expanded the therapeutic landscape of IBD. Landmark phase 3 trials in Crohn's disease (CD) and ulcerative colitis (UC) have demonstrated high efficacy and durable responses, followed by recent regulatory approvals across both indications. Notably, the SEQUENCE trial established the superiority of risankizumab over ustekinumab in achieving endoscopic and clinical endpoints in CD, underscoring the therapeutic value of IL-23p19 blockade and its differentiation from prior p40 inhibition. With additional agents in advanced development, IL-23p19 inhibitors are now emerging as a bona fide treatment class in IBD. Furthermore, IL-23p19 inhibitors display favorable safety profiles and convenient subcutaneous administration regimens, which broaden their applicability across diverse patient populations. However, key knowledge gaps remain regarding optimal treatment positioning, comparative effectiveness, and long-term disease outcomes. Precision medicine approaches will be crucial to fully exploit the potential of this drug class. For instance, early biomarkers can help monitor response, while future integration of serological and multi-omics biomarkers may enable the prediction of treatment success and guide personalized selection. This review summarizes the current knowledge base regarding IL-23p19 inhibitors in IBD, highlights their class effects and unique clinical value, and outlines a research agenda towards biomarker-driven and precision-guided use. Ultimately, IL-23p19-inhibition exemplifies how targeted immunotherapy and precision medicine can converge in order to reshape IBD management.</div>
            <div class="abs">Interleukin-23 (IL-23) is a pivotal cytokine driving intestinal inflammation in inflammatory bowel disease (IBD). The development of monoclonal antibodies selectively targeting the p19 subunit of IL-23, including risankizumab, mirikizumab and guselkumab, has significantly expanded the therapeutic landscape of IBD. Landmark phase 3 trials in Crohn's disease (CD) and ulcerative colitis (UC) have demonstrated high efficacy and durable responses, followed by recent regulatory approvals across both indications. Notably, the SEQUENCE trial established the superiority of risankizumab over ustekinumab in achieving endoscopic and clinical endpoints in CD, underscoring the therapeutic value of IL-23p19 blockade and its differentiation from prior p40 inhibition. With additional agents in advanced development, IL-23p19 inhibitors are now emerging as a bona fide treatment class in IBD. Furthermore, IL-23p19 inhibitors display favorable safety profiles and convenient subcutaneous administration regimens, which broaden their applicability across diverse patient populations. However, key knowledge gaps remain regarding optimal treatment positioning, comparative effectiveness, and long-term disease outcomes. Precision medicine approaches will be crucial to fully exploit the potential of this drug class. For instance, early biomarkers can help monitor response, while future integration of serological and multi-omics biomarkers may enable the prediction of treatment success and guide personalized selection. This review summarizes the current knowledge base regarding IL-23p19 inhibitors in IBD, highlights their class effects and unique clinical value, and outlines a research agenda towards biomarker-driven and precision-guided use. Ultimately, IL-23p19-inhibition exemplifies how targeted immunotherapy and precision medicine can converge in order to reshape IBD management.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41745409/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41745409')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41745409" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.\nğŸ¥ Journal of personalized medicine\nâš¡ âœ… ìš°ì„  ì ìš© ê³ ë ¤\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41745409/</textarea>
        </div>
    </details></div><div class='sec-group'><h3>ğŸº Liver Track</h3>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Journal of liver cancer</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Liver resection versus radiofrequency ablation or transarterial chemoembolization for early multinodular BCLC-A hepatocellular carcinoma: a systematic review and meta-analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> âœ… ìš°ì„  ì ìš© ê³ ë ¤</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Hepatocellular carcinoma (HCC) is the most common form of liver cancer, with high mortality rates worldwide. The optimal treatment strategy for patients with multinodular early-stage HCC (BCLC-A) is still controversial, particularly regarding liver resection (LR), radiofrequency ablation (RFA), and transarterial chemoembolization (TACE). This meta-analysis aims to evaluate the overall survival (OS) and disease-free survival (DFS) in patients with multinodular BCLC-A HCC treated with LR compared to RFA and TACE. A systematic literature review and meta-analysis were performed by searching PubMed, Embase, and the Cochrane Library for studies comparing LR with RFA and TACE. Pooled analyses of overall survival (OS) and disease-free survival (DFS) were performed using Hazard Ratios (HR) with 95% confidence intervals (CI). Fifteen studies, including two randomized controlled trials and 13 cohort studies, with a total of 2,869 patients, were included. LR was significantly associated with improved OS (HR 1.38; 95% CI 1.03-1.84; p = 0.01) and DFS (HR 2.16; 95% CI 1.26-3.70; p = 0.001) compared with RFA. Similarly, LR demonstrated superior OS (HR 2.11; 95% CI 1.37-3.25; p < 0.0001) and DFS (HR 2.77; 95% CI 1.04-7.36; p = 0.04) when compared with TACE. The more pronounced benefit observed for DFS likely reflects improved local tumor control achieved with surgical resection. In selected patients with multinodular BCLC-A HCC and preserved liver function (predominantly Child-Pugh A or B), LR is associated with significant improvements in OS and DFS compared with RFA and TACE when liver transplantation is not feasible. These findings support reconsideration of current treatment algorithms to prioritize LR in appropriately selected candidates.</div>
            <div class="abs">Hepatocellular carcinoma (HCC) is the most common form of liver cancer, with high mortality rates worldwide. The optimal treatment strategy for patients with multinodular early-stage HCC (BCLC-A) is still controversial, particularly regarding liver resection (LR), radiofrequency ablation (RFA), and transarterial chemoembolization (TACE). This meta-analysis aims to evaluate the overall survival (OS) and disease-free survival (DFS) in patients with multinodular BCLC-A HCC treated with LR compared to RFA and TACE. A systematic literature review and meta-analysis were performed by searching PubMed, Embase, and the Cochrane Library for studies comparing LR with RFA and TACE. Pooled analyses of overall survival (OS) and disease-free survival (DFS) were performed using Hazard Ratios (HR) with 95% confidence intervals (CI). Fifteen studies, including two randomized controlled trials and 13 cohort studies, with a total of 2,869 patients, were included. LR was significantly associated with improved OS (HR 1.38; 95% CI 1.03-1.84; p = 0.01) and DFS (HR 2.16; 95% CI 1.26-3.70; p = 0.001) compared with RFA. Similarly, LR demonstrated superior OS (HR 2.11; 95% CI 1.37-3.25; p < 0.0001) and DFS (HR 2.77; 95% CI 1.04-7.36; p = 0.04) when compared with TACE. The more pronounced benefit observed for DFS likely reflects improved local tumor control achieved with surgical resection. In selected patients with multinodular BCLC-A HCC and preserved liver function (predominantly Child-Pugh A or B), LR is associated with significant improvements in OS and DFS compared with RFA and TACE when liver transplantation is not feasible. These findings support reconsideration of current treatment algorithms to prioritize LR in appropriately selected candidates.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41742714/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41742714')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41742714" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Liver resection versus radiofrequency ablation or transarterial chemoembolization for early multinodular BCLC-A hepatocellular carcinoma: a systematic review and meta-analysis.\nğŸ¥ Journal of liver cancer\nâš¡ âœ… ìš°ì„  ì ìš© ê³ ë ¤\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41742714/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Giornale italiano di cardiologia (2006)</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>[Non-dilated left ventricular cardiomyopathy: beyond morphology, towards diagnostic precision].</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The introduction of non-dilated left ventricular cardiomyopathy (NDLVC) represents one of the key highlights of the 2023 European Society of Cardiology guidelines on cardiomyopathies. NDLVC is defined by the presence of left ventricular systolic dysfunction in the absence of ventricular dilation and/or non-ischemic myocardial fibrosis detectable by cardiac magnetic resonance. The clinical manifestation may be arrhythmogenic, with a risk of life-threatening ventricular arrhythmias even in patients with preserved ejection fraction. The phenotypic heterogeneity and variability in clinical expression reflect the complex interplay between genetic predisposition (involving variants in genes such as FLNC, DSP, and LMNA) and environmental, epigenetic, or inflammatory factors. A synergistic approach combining comprehensive clinical and family assessment, electrocardiographic and echocardiographic findings, advanced imaging, and genetic testing enables more accurate phenotypic characterization, definitive diagnosis, and consequently, tailored therapeutic strategies.</div>
            <div class="abs">The introduction of non-dilated left ventricular cardiomyopathy (NDLVC) represents one of the key highlights of the 2023 European Society of Cardiology guidelines on cardiomyopathies. NDLVC is defined by the presence of left ventricular systolic dysfunction in the absence of ventricular dilation and/or non-ischemic myocardial fibrosis detectable by cardiac magnetic resonance. The clinical manifestation may be arrhythmogenic, with a risk of life-threatening ventricular arrhythmias even in patients with preserved ejection fraction. The phenotypic heterogeneity and variability in clinical expression reflect the complex interplay between genetic predisposition (involving variants in genes such as FLNC, DSP, and LMNA) and environmental, epigenetic, or inflammatory factors. A synergistic approach combining comprehensive clinical and family assessment, electrocardiographic and echocardiographic findings, advanced imaging, and genetic testing enables more accurate phenotypic characterization, definitive diagnosis, and consequently, tailored therapeutic strategies.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41738421/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41738421')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41738421" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ [Non-dilated left ventricular cardiomyopathy: beyond morphology, towards diagnostic precision].\nğŸ¥ Giornale italiano di cardiologia (2006)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41738421/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>European journal of medical research</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Association of alkaline phosphatase, Î³-glutamyl transferase, total bilirubin, and bile acid levels with HCC risk: a systematic review and meta-analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>This meta-analysis suggests that elevated ALP, GGT, and TB might be associated with new-onset HCC, emphasizing the importance of monitoring these cholestasis-related parameters in clinical practice. BA could not be analyzed due to the small number of studies and the differences in reporting.</div>
            <div class="abs">Cholestasis-related parameters are indicators of liver inflammation and damage, which contribute to hepatocellular carcinoma (HCC) development.<br><br>This systematic review and meta-analysis explored the association between key cholestasis-related parameters and the risk of new-onset HCC.<br><br>PubMed, EMBASE, and the Cochrane Library were searched from inception to July 15, 2024, for eligible studies investigating the association between alkaline phosphatase (ALP), Î³-glutamyl transferase (GGT), bile acids (BA), and total bilirubin (TB) and incident HCC. The Newcastle-Ottawa Scale was used to evaluate the risk of bias. Random-effects model was used to pooled the estimates, and sensitivity analysis was conducted using fixed-effects models.<br><br>From 4053 entries, 155 studies were included (3,808,988 individuals). After confounder adjustment, elevated ALP (hazard ratios [HR]â€‰=â€‰2.49, 95% confidence interval [CI] 1.66-3.75), GGT (HRâ€‰=â€‰2.57, 95% CI 2.15-3.08), and TB (HRâ€‰=â€‰1.89, 95% CI 1.36-2.61) were associated with increased risks of new-onset HCC, consistent with sensitivity analysis using fixed effects models. The multivariable analyses of ALP, GGT, and TB as continuous variables showed no associations with the risk of HCC. In multivariable analyses using the most commonly employed cutoffs, GGTâ€‰>â€‰50 U/L (HRâ€‰=â€‰2.51, 95% CI 1.55-4.06) and TBâ€‰>â€‰1.2Â mg/dL (HRâ€‰=â€‰2.94, 95% CI 1.67-5.20) were independently associated with incident HCC.<br><br>This meta-analysis suggests that elevated ALP, GGT, and TB might be associated with new-onset HCC, emphasizing the importance of monitoring these cholestasis-related parameters in clinical practice. BA could not be analyzed due to the small number of studies and the differences in reporting.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41749290/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41749290')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41749290" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Association of alkaline phosphatase, Î³-glutamyl transferase, total bilirubin, and bile acid levels with HCC risk: a systematic review and meta-analysis.\nğŸ¥ European journal of medical research\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41749290/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"><span class='badge if'>IF 13.5</span> <b>Hepatology (Baltimore, Md.)</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Dynamic radiomic changes effectively predict pCR in uHCC after conversion therapy. Combining delta radiomics with AFP response significantly improves predictive performance, offering a non-invasive method for assessing pCR and potentially guiding personalized treatment decisions.</div>
            <div class="abs">Pathological complete response (pCR) following conversion therapy for initially unresectable hepatocellular carcinoma (uHCC) remains challenging to predict preoperatively. This study developed and validated a model integrating clinicopathological and radiomic features of tumor to predict pCR.<br><br>In this multi-center retrospective study, temporal radiomics features were extracted from baseline, post-treatment, and delta (change) MRIs. Serum AFP response was calculated as logâ‚â‚€(preoperative AFP)/logâ‚â‚€(baseline AFP). Univariate analysis, collinearity assessment, LASSO, and random forest were employed to perform feature selection. Fourteen machine learning models were benchmarked, with performance evaluated by using comprehensive metrics AUC, NPV, PPV, sensitivity, specificity, calibration, and decision curve analysis.<br><br>The model was developed and validated in a training (n=78), an internal test (n=32), and an independent validation cohort (n=44). The delta radiomic model significantly outperformed both baseline (test AUC: 0.835 vs. 0.483, p<0.05; validation AUC: 0.783 vs. 0.434, p<0.05) and preoperative models (test AUC: 0.685, p<0.05; validation AUC: 0.506, p<0.05), demonstrating superior predictive performance and generalization capability in predicting lesion-level pCR. Notably, when predicting patient-level pCR, the radiomic model also showed robust discrimination, with AUCs of 0.819 in the test set and 0.781 in the validation set.The combined radiomics-AFP model achieved even higher AUCs of 0.920 (test) and 0.857 (validation) in predicting lesion-level pCR.<br><br>Dynamic radiomic changes effectively predict pCR in uHCC after conversion therapy. Combining delta radiomics with AFP response significantly improves predictive performance, offering a non-invasive method for assessing pCR and potentially guiding personalized treatment decisions.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41746634/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41746634')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41746634" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.\nğŸ¥ Hepatology (Baltimore, Md.)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41746634/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Toxins</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Aflatoxin and Liver Cancer in China: The Evolving Research Landscape.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Aflatoxins, particularly aflatoxin B</div>
            <div class="abs">Aflatoxins, particularly aflatoxin B</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41745727/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41745727')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41745727" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Aflatoxin and Liver Cancer in China: The Evolving Research Landscape.\nğŸ¥ Toxins\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41745727/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Journal of proteome research</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Enrichment and Preservation of Urine Metabolites Using Styrene Divinylbenzene Reversed Phase Sulfonate (SDB-RPS) Disks for Enhanced Biomarker Discovery and Disease Monitoring.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Urine metabolomics plays a crucial role in biomarker discovery and disease monitoring, but challenges in metabolite preservation remain. This study evaluates the use of styrene divinylbenzene reversed phase sulfonate (SDB-RPS) disks for enriching and preserving urine metabolites utilizing ultraperformance liquid chromatography-mass spectrometry (UPLC-MS) for analysis. We compared SDB-RPS-enriched urine samples with untreated urine across three experimental parts: (1) metabolic profiling using C18 and HILIC chromatography under both positive and negative ion modes; (2) degradation kinetics, where SDB-RPS and untreated urine samples were incubated at 55, 65, and 75 Â°C with constant humidity (75%); and (3) disease classification using hepatitis (</div>
            <div class="abs">Urine metabolomics plays a crucial role in biomarker discovery and disease monitoring, but challenges in metabolite preservation remain. This study evaluates the use of styrene divinylbenzene reversed phase sulfonate (SDB-RPS) disks for enriching and preserving urine metabolites utilizing ultraperformance liquid chromatography-mass spectrometry (UPLC-MS) for analysis. We compared SDB-RPS-enriched urine samples with untreated urine across three experimental parts: (1) metabolic profiling using C18 and HILIC chromatography under both positive and negative ion modes; (2) degradation kinetics, where SDB-RPS and untreated urine samples were incubated at 55, 65, and 75 Â°C with constant humidity (75%); and (3) disease classification using hepatitis (</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41744491/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41744491')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41744491" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Enrichment and Preservation of Urine Metabolites Using Styrene Divinylbenzene Reversed Phase Sulfonate (SDB-RPS) Disks for Enhanced Biomarker Discovery and Disease Monitoring.\nğŸ¥ Journal of proteome research\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41744491/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Liver international : official journal of the International Association for the Study of the Liver</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Saroglitazar 4â€‰Mg in Metabolic Dysfunction-Associated Steatotic Liver Disease: 24-Week Results From Phase 4 Study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Saroglitazar 4â€‰mg for 24â€‰weeks was associated with improvements in surrogate markers of liver injury, steatosis, glycaemic control and lipid metabolism, with good tolerability. These interim real-world findings support further evaluation in the planned 52-week analysis.</div>
            <div class="abs">Saroglitazar magnesium, a dual PPAR Î±/Î³ agonist, is approved in India for the treatment of non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD). While controlled trials with saroglitazar have demonstrated improvements in hepatic and metabolic parameters in patients with MASLD, real-world data in populations with diverse metabolic comorbidities remain limited.<br><br>This is an ongoing, prospective, single-arm, multicenter, real-world, phase 4 study evaluating the effectiveness and safety of saroglitazar 4â€‰mg once daily in patients with MASLD. The current interim analysis includes 500 patients who completed 24â€‰weeks of treatment. Changes in liver stiffness measurement (LSM), hepatic steatosis (CAP and UAP), glycemic control, lipid profile, liver enzymes and non-invasive fibrosis scores were assessed. Safety was evaluated based on treatment-emergent adverse events (TEAEs). This was a non-protocol-defined, exploratory interim analysis; all statistical inferences are descriptive and p-values are nominal.<br><br>At baseline, the mean age was 45.7â€‰Â±â€‰11.6â€‰years, weight 81.0â€‰Â±â€‰13.6â€‰kg, body mass index (BMI) 29.9â€‰Â±â€‰4.7â€‰kg/m<br><br>In this interim real-world analysis, saroglitazar 4â€‰mg was associated with improvements in liver stiffness, hepatic steatosis, metabolic parameters and non-invasive fibrosis markers in patients with MASLD. The treatment was generally well tolerated. These findings warrant further confirmation upon completion of the 52-week analysis.<br><br>Saroglitazar 4â€‰mg for 24â€‰weeks was associated with improvements in surrogate markers of liver injury, steatosis, glycaemic control and lipid metabolism, with good tolerability. These interim real-world findings support further evaluation in the planned 52-week analysis.<br><br>CTRI/2023/05/053326 [Registered on: 31/05/2023].</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41742827/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41742827')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41742827" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Saroglitazar 4â€‰Mg in Metabolic Dysfunction-Associated Steatotic Liver Disease: 24-Week Results From Phase 4 Study.\nğŸ¥ Liver international : official journal of the International Association for the Study of the Liver\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41742827/</textarea>
        </div>
    </details></div><div class='sec-group'><h3>ğŸ§¬ Biliary/Pancreas</h3>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"><span class='badge if'>IF 13.5</span> <b>JHEP reports : innovation in hepatology</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>HCC recurrence in liver transplants treated with hypothermic oxygenated machine perfusion: An international matched cohort study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>HCC recurrence was rare after transplantation of livers treated with HOPE. Long-term survival in HOPE-treated HCC recipients was significantly better than in those receiving non-perfused livers, and comparable to outcomes in non-HCC recipients. These findings warrant validation in a randomized clinical trial.</div>
            <div class="abs">Liver transplantation (LT) for hepatocellular carcinoma (HCC) is performed worldwide, with 5-year survival rates of approximately 70%. However, post-transplant HCC recurrence occurs in 15-20% of recipients. We aimed to evaluate, for the first time, long-term recurrence-free survival in a large international cohort of patients undergoing LT for HCC using grafts treated with hypothermic oxygenated machine perfusion (HOPE).<br><br>This observational <br><br>The overall HCC recurrence rate in the HOPE-REAL cohort was 6.9% (41/599), with no significant difference between DBD and DCD liver transplants (7.1% [25/350] <br><br>HCC recurrence was rare after transplantation of livers treated with HOPE. Long-term survival in HOPE-treated HCC recipients was significantly better than in those receiving non-perfused livers, and comparable to outcomes in non-HCC recipients. These findings warrant validation in a randomized clinical trial.<br><br>This <br><br>NCT05520320.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41737541/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41737541')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41737541" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ HCC recurrence in liver transplants treated with hypothermic oxygenated machine perfusion: An international matched cohort study.\nğŸ¥ JHEP reports : innovation in hepatology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41737541/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Frontiers in pharmacology</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously. These results support the continued safe use of GLP-1 RAs in T2DM and obesity, although longer trials with cancer-specific endpoints are warranted. This review was registered in Open Science Framework https://osf.io/3rv6d/overview.</div>
            <div class="abs">Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for type 2 diabetes mellitus (T2DM) and obesity. While their metabolic benefits are established, concerns persist about a possible link with gastrointestinal (GI) cancers. This study aimed to clarify the association between GLP-1 RA use and GI cancer risk.<br><br>A systematic search of PubMed, Embase, and Scopus till August 2024 identified randomized controlled trials (RCTs) reporting GI cancer outcomes. Ninety-three RCTs with 1.85 million participants were included. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random-effects model, with subgroup analyses by cancer type and exposure duration.<br><br>GLP-1 RA use was not associated with an increased overall risk of GI cancers (HR 0.81: 95% CI: 0.68-0.96). Subgroup analyses indicated reduced risks of colorectal cancer (HR 0.81: 95% CI: 0.68-0.96) and liver cancer (HR: 0.74; 95% CI: 0.62-0.88). Pancreatic cancer risk was not significantly elevated (HR: 0.78; 95% CI: 0.61-0.95). Findings were consistent across sensitivity analyses.<br><br>This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously. These results support the continued safe use of GLP-1 RAs in T2DM and obesity, although longer trials with cancer-specific endpoints are warranted. This review was registered in Open Science Framework https://osf.io/3rv6d/overview.<br><br>https://osf.io/3rv6d/overview.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41743116/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41743116')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41743116" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.\nğŸ¥ Frontiers in pharmacology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41743116/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>The oncologist</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella Study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The overall safety of atezolizumab combinations was manageable and consistent with each agent's known safety profile. This novel trial design enabled rapid evaluations of three atezolizumab combinations; all had limited efficacy as 2â€‰L or 3â€‰L treatment for metastatic PDAC. New treatments are needed to improve outcomes in previously treated PDAC.</div>
            <div class="abs">The MORPHEUS platform comprised multiple open-label, randomized, phase Ib/II trials to identify early signals with different treatment combinations across multiple cancers. MORPHEUS-PDAC (NCT03193190) evaluated atezolizumab combinations in pancreatic ductal adenocarcinoma (PDAC). We describe outcomes with atezolizumab plus either motixafortide, cobimetinib, or two simlukafusp alfa regimens.<br><br>Eligible patients with advanced, pretreated PDAC were randomized to receive second-line (2â€‰L) atezolizumab plus either motixafortide (BL8040; nâ€‰=â€‰15), cobimetinib (nâ€‰=â€‰14), simlukafusp alfa every 2â€‰weeks (q2w; nâ€‰=â€‰15), or simlukafusp alfa every 3â€‰weeks (q3w; nâ€‰=â€‰16); or control (mFOLFOX6 [nâ€‰=â€‰25] or gemcitabine plus nab-paclitaxel [nâ€‰=â€‰25]). Patients experiencing disease progression or toxicity who met eligibility criteria were enrolled to receive third-line (3â€‰L) atezolizumab plus cobimetinib (nâ€‰=â€‰14), or atezolizumab plus simlukafusp alfa q2w (nâ€‰=â€‰1) or q3w (nâ€‰=â€‰6). Primary endpoints were objective response rates (ORRs) per RECIST 1.1 and safety.<br><br>ORRs were 7.1% with atezolizumab-simlukafusp alfa q2w, 8.7% with mFOLFOX6 (both 2â€‰L; 0% in other arms), 14.3% with atezolizumab-cobimetinib, and 16.7% with atezolizumab-simlukafusp alfa q3w (both 3â€‰L). Grade 3-5 adverse event rates were 53.3% (2â€‰L atezolizumab-motixafortide), 64.3% (2â€‰L atezolizumab-cobimetinib), 57.1% (2â€‰L atezolizumab-simlukafusp alfa q2w), 53.3% (2â€‰L atezolizumab-simlukafusp alfa q3w), 63.0% (2â€‰L mFOLFOX6 or gemcitabine-nab-paclitaxel), 50.0% (3â€‰L atezolizumab-cobimetinib), and 100% (3â€‰L atezolizumab-simlukafusp alfa q3w).<br><br>The overall safety of atezolizumab combinations was manageable and consistent with each agent's known safety profile. This novel trial design enabled rapid evaluations of three atezolizumab combinations; all had limited efficacy as 2â€‰L or 3â€‰L treatment for metastatic PDAC. New treatments are needed to improve outcomes in previously treated PDAC.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41741368/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41741368')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41741368" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella Study.\nğŸ¥ The oncologist\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41741368/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Dual calcium-ACE inhibition reverses non alcoholic fatty pancreas progression: Mechanistic convergence on miR-762/GPX4 driven NLRP3 inflammasome activation.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>These findings position miR-762 as a linchpin biomarker connecting metabolic stress to ferroptotic pancreatitis, with clinical translation challenges. This work provides the first evidence that sub-therapeutic calcium-RAS crosstalk modulation can reverse established pancreatic steatosis while outlining a precision medicine framework for NAFP prevention.</div>
            <div class="abs">Non-alcoholic fatty pancreas (NAFP) is characterized by abnormal pancreatic fat accumulation and remains poorly understood.<br><br>This study investigates the therapeutic potential and mechanistic basis of low-dose amlodipine-perindopril combination therapy, hypothesizing dual calcium channel blockade and RAS inhibition synergistically disrupt ferroptotic-inflammatory cascades driving pancreatic lipotoxicity.<br><br>The bioinformatics analysis of GEO datasets (GSE40901, GSE101462, and GSE194331) identified differentially expressed genes, which were further validated through molecular docking studies with amlodipine and perindoprilat. Male Wistar rats (nâ€¯=â€¯30) were randomized into five groups: healthy control, NAFP (high-sugar/high-fat diet), amlodipine-treated, perindopril-treated, and combination therapy. Gene expression of GPX4, ACSL4, NLRP3, and rno-miR-762 was quantified by Real-Time PCR. Metabolic parameters, pancreatic histopathology, and immunohistochemical markers (caspase-1, nuclear factor kappa B (NF-ÎºB)) were assessed.<br><br>Bioinformatics analysis revealed significant alterations in ferroptosis and inflammatory pathways. Molecular docking demonstrated favorable binding affinities between therapeutic compounds and target proteins. NAFP induction resulted in GPX4 downregulation (0.471â€¯Â±â€¯0.357 vs. 1.197â€¯Â±â€¯0.449, Pâ€¯<â€¯0.05), ACSL4 upregulation (48.633â€¯Â±â€¯40.998 vs. 1.197â€¯Â±â€¯0.445, pâ€¯<â€¯0.001), elevated NLRP3 (12.717â€¯Â±â€¯7.904 vs. 1.115â€¯Â±â€¯0.186, pâ€¯<â€¯0.001), and increased rno-miR-762 expression. The combination therapy achieved 73â€¯% reduction in pancreatic adipocyte area (vs. 42â€¯% with monotherapies, pâ€¯<â€¯0.001) through coordinated miR-762 suppression (â†“68â€¯%, q=0.003) and GPX4 protein restoration (â†‘2.1-fold, pâ€¯=â€¯0.008). NLRP3 inflammasome activity decreased by 89â€¯% (pâ€¯=â€¯0.004). Crucially, the regimen preserved hemodynamic stability, demonstrating metabolic benefits without cardiovascular compromise.<br><br>These findings position miR-762 as a linchpin biomarker connecting metabolic stress to ferroptotic pancreatitis, with clinical translation challenges. This work provides the first evidence that sub-therapeutic calcium-RAS crosstalk modulation can reverse established pancreatic steatosis while outlining a precision medicine framework for NAFP prevention.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41740369/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41740369')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41740369" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Dual calcium-ACE inhibition reverses non alcoholic fatty pancreas progression: Mechanistic convergence on miR-762/GPX4 driven NLRP3 inflammasome activation.\nğŸ¥ Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41740369/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Cancer research communications</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 Study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Lenvatinib plus pembrolizumab demonstrated modest antitumor activity and a manageable safety profile in previously treated, advanced gastric cancer, BTC, and PDAC.</div>
            <div class="abs">Patients with gastric cancer, biliary tract cancer (BTC), and pancreatic ductal adenocarcinoma (PDAC) have poor survival outcomes and limited second- or later-line treatment options. Certain drugs targeting vascular endothelial growth factor (VEGF) or programmed cell death protein 1 (PD-1) signaling pathways are currently used in these cancers in specific circumstances; however, there remains a need for novel treatment combinations. LEAP-005 is a multicohort, open-label, phase 2 study that evaluated lenvatinib (multitargeted inhibitor of tyrosine kinases, including VEGF) plus pembrolizumab (antiâ€’PD-1 monoclonal antibody) in select previously treated solid tumors.<br><br>Participants with previously treated, advanced gastric cancer, BTC, and PDAC were enrolled in cohorts C, F, and G of LEAP-005, respectively, and received lenvatinib 20 mg/day orally plus pembrolizumab 200 mg intravenously every 3 weeks. Primary endpoints were objective response rate (ORR) and safety.<br><br>Of 99, 102, and 103 total participants enrolled in cohorts C, F, and G, respectively, median times from first dose of study treatment to data cutoff (February 6, 2023) were 23.7, 24.2, and 19.5 months. ORRs (95% CI) by blinded independent central review were 15.2% (8.7%â€’23.8%) in cohort C, 17.6% (10.8%â€’26.4%) in cohort F, and 7.8% (3.4%â€’14.7%) in cohort G. Grade 3â€’5 treatment-related adverse events occurred in 54.5% of participants in cohort C, and grade 3â€’4 (no grade 5) occurred in 60.8% and 59.2% of participants in cohorts F and G, respectively.<br><br>Lenvatinib plus pembrolizumab demonstrated modest antitumor activity and a manageable safety profile in previously treated, advanced gastric cancer, BTC, and PDAC.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41747221/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41747221')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41747221" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 Study.\nğŸ¥ Cancer research communications\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41747221/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Neurobiology of disease</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Unveiling the hidden genetic conundrum linking pulmonary diseases and neuropsychiatric disorders: Novel insights from advanced omics-based analyses of the lung-brain axis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>These findings indicate that pleiotropic genetic factors connecting pulmonary and neuropsychiatric diseases are widely distributed throughout the genome. This provides robust evidence for a shared genetic basis underlying the lung-brain axis and has important implications for the potential for developing targeted intervention and treatment that simultaneously address both diseases types.</div>
            <div class="abs">This study seeks to elucidate the shared genetic underpinnings between these pulmonary diseases and neuropsychiatric disorders, focusing on common genomic loci, implicated genes, and biochemical pathways.<br><br>This study is a genome-wide pleiotropic association study that utilized genome-wide association summary statistics from publicly available data sources. Diverse bioinformatics and statistical genetics strategies were applied to sequentially investigate the pleiotropic associations from single-nucleotide variant (SNV), gene-level data, and biological pathways, with the aim to better understand the shared genetic etiology between 3 pulmonary diseases and 7 neuropsychiatric disorders.<br><br>Significant genetic correlations and overlaps were observed among 20 of the 21 trait pairs. Pleiotropic analysis, using a composite null hypothesis, identified 3962 potentially pleiotropic SNVs across 20 trait pairs, along with 31 pleiotropic loci and 3 colocalized loci. Gene-based analysis revealed 103 unique candidate pleiotropic genes, which were notably enriched in phenotypes and tissues associated with the lung-brain axis (LBA). Pathway enrichment analysis highlighted key biological processes related to cell adhesion, synaptic structure and function, and immune cell differentiation. Several pleiotropic loci were also found to share causal variants with lung-related phenotypes. Mendelian randomization analysis suggested vertical pleiotropy across 8 trait pairs.<br><br>These findings indicate that pleiotropic genetic factors connecting pulmonary and neuropsychiatric diseases are widely distributed throughout the genome. This provides robust evidence for a shared genetic basis underlying the lung-brain axis and has important implications for the potential for developing targeted intervention and treatment that simultaneously address both diseases types.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41747966/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41747966')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41747966" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Unveiling the hidden genetic conundrum linking pulmonary diseases and neuropsychiatric disorders: Novel insights from advanced omics-based analyses of the lung-brain axis.\nğŸ¥ Neurobiology of disease\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41747966/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>iScience</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Deficiency of Werner RecQ-type DNA helicase causes premature malnutrition in zebrafish.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Werner syndrome is a genetic progeria characterized by premature aging symptoms, but its early-onset pathology remains unclear. We generated </div>
            <div class="abs">Werner syndrome is a genetic progeria characterized by premature aging symptoms, but its early-onset pathology remains unclear. We generated </div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41732282/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41732282')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41732282" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Deficiency of Werner RecQ-type DNA helicase causes premature malnutrition in zebrafish.\nğŸ¥ iScience\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41732282/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Medicine</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Exploring dietary habits strongly associated with pancreatic cancer from the perspective of Mendelian randomization.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>While some retrospective studies have reported that certain dietary habits may affect pancreatic cancer, the variety of dietary habits studied has been limited. A 2-sample Mendelian randomization (MR) analysis was performed using exposure data from the UK Biobank data (nâ€…=â€…10,019,305) and outcome data from the FinnGen database (731 pancreatic cancer cases and 314,193 controls). Instrumental variables were selected based on genome-wide significance, followed by linkage disequilibrium clumping. Sensitivity analyses, including Steiger filtering and MR-PRESSO, were conducted to ensure the robustness of the causal inferences. Following this process, we extracted and filtered the data, ultimately selecting 30 dietary phenotypes from the original 231. Our findings revealed that alcohol intake frequency (raw P-valueâ€…=.002, odds ratio (OR)â€…=â€…1.090, 95% CI: 1.032-1.151) and average weekly spirits intake (raw P-valueâ€…=â€….005, ORâ€…=â€…1.793, 95% CI: 1.196-2.688) were risk factors for pancreatic cancer using data from 706 single nucleotide polymorphisms derived from FinnGen database. Notably, cooked vegetable intake (raw P-valueâ€…=â€….029, ORâ€…=â€…0.704, 95% CI: 0.514-0.965) was found to have a protective effect against pancreatic cancer. Our MR analysis provides evidence that specific dietary habits significantly influence pancreatic cancer risk, highlighting the potential of dietary interventions within public health strategies for pancreatic cancer management.</div>
            <div class="abs">While some retrospective studies have reported that certain dietary habits may affect pancreatic cancer, the variety of dietary habits studied has been limited. A 2-sample Mendelian randomization (MR) analysis was performed using exposure data from the UK Biobank data (nâ€…=â€…10,019,305) and outcome data from the FinnGen database (731 pancreatic cancer cases and 314,193 controls). Instrumental variables were selected based on genome-wide significance, followed by linkage disequilibrium clumping. Sensitivity analyses, including Steiger filtering and MR-PRESSO, were conducted to ensure the robustness of the causal inferences. Following this process, we extracted and filtered the data, ultimately selecting 30 dietary phenotypes from the original 231. Our findings revealed that alcohol intake frequency (raw P-valueâ€…=.002, odds ratio (OR)â€…=â€…1.090, 95% CI: 1.032-1.151) and average weekly spirits intake (raw P-valueâ€…=â€….005, ORâ€…=â€…1.793, 95% CI: 1.196-2.688) were risk factors for pancreatic cancer using data from 706 single nucleotide polymorphisms derived from FinnGen database. Notably, cooked vegetable intake (raw P-valueâ€…=â€….029, ORâ€…=â€…0.704, 95% CI: 0.514-0.965) was found to have a protective effect against pancreatic cancer. Our MR analysis provides evidence that specific dietary habits significantly influence pancreatic cancer risk, highlighting the potential of dietary interventions within public health strategies for pancreatic cancer management.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41731762/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41731762')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41731762" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Exploring dietary habits strongly associated with pancreatic cancer from the perspective of Mendelian randomization.\nğŸ¥ Medicine\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41731762/</textarea>
        </div>
    </details></div>
    </div>

    <footer style="text-align:center; padding:15px; color:#95a5a6; font-size:0.75rem;">ğŸš€ Project: MedProductive Clinical AI</footer>

    <script>
        function toggleF() {
            const btn = document.getElementById('fBtn'); btn.classList.toggle('active');
            const isF = btn.classList.contains('active');
            btn.style.background = isF ? 'var(--success)' : '#fff';
            btn.style.color = isF ? '#fff' : 'var(--success)';
            document.querySelectorAll('.paper-item').forEach(p => {
                p.style.display = isF ? (p.querySelector('.badge-guideline') ? 'block' : 'none') : 'block';
            });
        }
        function copyShare(id) {
            const el = document.getElementById('s_'+id);
            navigator.clipboard.writeText(el.value.replace(/\\n/g, '\n')).then(() => alert("âœ… ë³µì‚¬ ì™„ë£Œ!"));
        }
        
        // ë„ë„› ì°¨íŠ¸ë§Œ ë Œë”ë§
        new Chart(document.getElementById('c2'), { 
            type:'doughnut', 
            data:{ labels:["GI", "Liver", "Biliary/Pancreas"], datasets:[{data:[8, 7, 8], backgroundColor:['#e74c3c','#f1c40f','#2ecc71']}] }, 
            options: { 
                responsive: true, 
                maintainAspectRatio: false, 
                plugins: { 
                    legend: { position: 'right', labels: { font: { size: 10 } } } 
                } 
            } 
        });
    </script>
</body>
</html>
